Systematic Review of Real-World Data: Assessing Cancer, Major Adverse Cardiovascular Events, Venous Thromboembolism, Infection, and Mortality Risk Associated With JAK Inhibitors in Rheumatoid Arthritis Patients in the United States

Janus kinase inhibitors (JAKi) are novel oral therapy option for rheumatoid arthritis (RA) patients. However, data from the randomized controlled trials (RCTs) found an increased risk of cancer, serious cardiovascular events, blood clots, and death with JAKi. Patients enrolled in RCTs do not represent general patient population in real world. It is essential to complete the body of evidence with real-world data (RWD).https://egrove.olemiss.edu/pharm_annual_posters_2024/1007/thumbnail.jp

Adherence to Janus Kinase Inhibitors Among Older Adults with Rheumatoid Arthritis Initiating New Treatment

Janus Kinase Inhibitors (JAKIs) are a recent advancement in Rheumatoid Arthritis (RA) treatment, offering an effective oral therapy option. However, adherence to JAKIs in RA patients is suboptimal compared to injectable options. Additionally, there is limited research on adherence to JAKIs among older adults in the United States. The study in question focused on examining JAKIs adherence in older RA patients enrolled in Medicare and identifying factors contributing to poor adherence.https://egrove.olemiss.edu/pharm_annual_posters_2024/1006/thumbnail.jp

Trends and Regional Variation in New Opioid Prescriptions and Long-Term Prescription Opioid Use among Older Adults in the United States, 2012-2020

Corresponding with CDC’s Guideline for Prescribing Opioids for Chronic Pain in 2016, policies and procedures enacted by private and public institutions, prescriptions for opioid medications have been declining. However, the trends of opioid use change among older adults remains poorly understood, probably because older people are not at the center stage of the national opioid crisis. This study aimed to provide updates on utilization and trends in new opioid prescriptions and new long-term opioid episode among older adults enrolled in Medicare.https://egrove.olemiss.edu/pharm_annual_posters_2024/1009/thumbnail.jp

Opioid Tapering and Its Associations with Risk of Opioid Use Disorder and Mortality Among Older Adults

Corresponding with CDC’s Guideline for Prescribing Opioids for Chronic Pain in 2016 and policies and procedures enacted by payers, quality organizations, and state agencies, prescriptions for opioid medications have witnessed a sharp decreasing trend with increases in opioid dose tapering and discontinuation. But opioid-related mortality has not shown a parallel decline. Several observational studies have explored the potential adverse effects of opioid dose tapering and discontinuation, with a growing focus on the rate of dose tapering. We hypothesized that many of the negative consequences of opioid tapering may be associated with the rate of opioid tapering or discontinuation.https://egrove.olemiss.edu/pharm_annual_posters_2024/1005/thumbnail.jp